Use of liquid chromatography-tandem mass spectrometry for foscarnet quantification in human serum and cerebrospinal fluid.
Journal
Rapid communications in mass spectrometry : RCM
ISSN: 1097-0231
Titre abrégé: Rapid Commun Mass Spectrom
Pays: England
ID NLM: 8802365
Informations de publication
Date de publication:
15 Apr 2022
15 Apr 2022
Historique:
revised:
27
12
2021
received:
18
10
2021
accepted:
05
01
2022
pubmed:
11
1
2022
medline:
23
3
2022
entrez:
10
1
2022
Statut:
ppublish
Résumé
Foscarnet (FCV) is used to treat cytomegalovirus, human herpesvirus, and human immunodeficiency virus infections. It is a low-molecular-weight compound containing carboxylate and phosphate groups. There are no reports on the use of liquid chromatography-tandem mass spectrometry (LC/MS/MS) to analyze FCV via bioanalysis. In the present study, we developed the ion-pair LC/MS/MS method to analyze FCV in human serum and cerebrospinal fluid (CSF). FCV was extracted from human serum and CSF by weak anion exchange (WAX) solid-phase extraction. The LC/MS/MS systems were coated with 0.1% phosphoric acid in methanol to avoid nonspecific absorption. FCV was detected using ion-pair LC/MS/MS with dibutylammonium acetate. Selected reaction monitoring transition of FCV in the negative ion mode was selected at m/z 125.1 → 62.9. FCV was selectively detected in human serum and CSF, and the liner range was 5-1000 μM (R A robust LC/MS/MS method to analyze FCV was successfully developed. FCV was selectively measured using LC/MS/MS in very low extract volumes (20 μL). The method will be useful in evaluating the FCV level in human serum and CSF.
Substances chimiques
Foscarnet
364P9RVW4X
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e9255Informations de copyright
© 2022 John Wiley & Sons Ltd.
Références
Wagstaff AJ, Bryson HM. Foscarnet. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with viral infections. Drugs. 1994;48(2):199-226. doi:10.2165/00003495-199448020-00007
Crumpacker CS. Mechanism of action of foscarnet against viral polymerases. Am J Med. 1992;92(2A):3S-7S. doi:10.1016/0002-9343(92)90329-a
Jacobson MA. Review of the toxicities of foscarnet. J Acquir Immune Defic Syndr (1988). 1992;5(suppl 1):S11-S17.
Aweeka F, Gambertoglio J, Mills J, Jacobson MA. Pharmacokinetics of intermittently administered intravenous foscarnet in the treatment of acquired immunodeficiency syndrome patients with serious cytomegalovirus retinitis. Antimicrob Agents Chemother. 1989;33(5):742-745. doi:10.1128/AAC.33.5.742
Raffi F, Taburet AM, Ghaleh B, Huart A, Singlas E. Penetration of foscarnet into cerebrospinal fluid of AIDS patients. Antimicrob Agents Chemother. 1993;37(9):1777-1780. doi:10.1128/AAC.37.9.1777
Hengge UR, Brockmeyer NH, Malessa R, Ravens U, Goos M. Foscarnet penetrates the blood-brain barrier: Rationale for therapy of cytomegalovirus encephalitis. Antimicrob Agents Chemother. 1993;37(5):1010-1014. doi:10.1128/AAC.37.5.1010
Pettersson KJ, Nordgren T, Westerlund D. Determination of phosphonoformate (foscarnet) in biological fluids by ion-pair reversed-phase liquid chromatography. J Chromatogr. 1989;488(2):447-455. doi:10.1016/s0378-4347(00)82968-0
Hassanzadeh MK, Aweeka FT, Wu S, Jacobson MA, Gambertoglio JG. Determination of phosphonoformic acid in human plasma and urine by high-performance liquid chromatography with electrochemical detection. J Chromatogr. 1990;525(1):133-140. doi:10.1016/s0378-4347(00)83386-1
Ba BB, Corniot AG, Ducint D, Breilh D, Grellet J, Saux MC. Determination of phosphonoformate (foscarnet) in calf and human serum by automated solid-phase extraction and high-performance liquid chromatography with amperometric detection. J Chromatogr B. 1999;724(1):127-136. doi:10.1016/s0378-4347(98)00582-9
Abdel-Hamid ME. Comparative LC-MS and HPLC analyses of selected antiepileptics and beta-blocking drugs. Farmacoterapia. 2000;55(2):136-145. doi:10.1016/s0014-827x(00)00006-9
Tuzimski T, Petruczynik A. Review of chromatographic methods coupled with modern detection techniques applied in the therapeutic drugs monitoring (TDM). Molecules. 2020;25(17). doi:10.3390/molecules25174026
US Department of Health and Human Services, Food and Drug Administration. Bioanalytical method validation guidance for industry. https://www.fda.gov/files/drugs/published/Bioanalytical-Method-Validation-Guidance-for-Industry.pdf; 2018.
Warren S, Williams MR. The acid-catalysed decarboxylation of phosphonoformic acid. J Chem Soc B. 1971;618-621. doi:10.1039/j29710000618
Fu X, Deja S, Kucejova B, Duarte JAG, McDonald JG, Burgess SC. Targeted determination of tissue energy status by LC-MS/MS. Anal Chem. 2019;91(9):5881-5887. doi:10.1021/acs.analchem.9b00217
Birdsall RE, Gilar M, Shion H, Yu YQ, Chen W. Reduction of metal adducts in oligonucleotide mass spectra in ion-pair reversed-phase chromatography/mass spectrometry analysis. Rapid Commun Mass Spectrom. 2016;30(14):1667-1679. doi:10.1002/rcm.7596
Wakamatsu A, Morimoto K, Shimizu M, Kudoh S. A severe peak tailing of phosphate compounds caused by interaction with stainless steel used for liquid chromatography and electrospray mass spectrometry. J Sep Sci. 2005;28(14):1823-1830. doi:10.1002/jssc.200400027